Available animal and cell line models have suggested that specific therapeutics might be effective in treating Middle East respiratory syndrome (MERS). We conducted a systematic review of evidence for treatment with pharmacologic and supportive therapies. We developed a protocol and searched 5 databases for studies describing treatment of MERS and deaths in MERS patients. Risk of bias (RoB) was assessed by using ROBINS-I tool. We retrieved 3,660 unique citations; 20 observational studies met eligibility, and we studied 13 therapies. Most studies were at serious or critical RoB; no studies were at low RoB. One study, at moderate RoB, showed reduced mortality rates in severe MERS patients with extracorporeal membrane oxygenation; no other studies showed a significant lifesaving benefit to any treatment. The existing literature on treatments for MERS is observational and at moderate to critical RoB. Clinical trials are needed to guide treatment decisions.
【저자키워드】 viruses, respiratory infections, zoonoses, convalescent plasma, Intravenous immunoglobulin, coronavirus, Corticosteroids, acute respiratory distress syndrome, antivirals, interferon, systematic review, MERS, ribavirin, Coronavirus infections, Severe acute respiratory syndrome, CoV, supportive care, Middle East respiratory syndrome, 【초록키워드】 Treatment, protocol, Trial, database, observational study, clinical, death, membrane, mortality rate, Critical, moderate, Therapies, Evidence, Middle East, supportive therapies, syndrome, eligibility, cell line, MOST, effective, benefit, conducted, reduced, searched, unique, suggested, MERS patient, MERS patients, retrieved, RoB, 【제목키워드】 respiratory, Middle East, Pharmacologic,